Your Leader in Ophthalmic APIs

They have recently expanded their customs Storage and Transit Document Management. With a complete customs service portfolio near Frankfurt International Airport, Logistics4Pharma provides fast and reliable customs solutions, enhancing flexibility and efficiency for global supply chains.

As the global leader in Ophthalmic APIs, C2 PHARMA was asked to participate in Pharmasource’s buyer guide focused on Ophthalmics.

C2 PHARMA, the global leader in manufacturing and supplying ophthalmic and niche active pharmaceutical ingredients (APIs), proudly announces the approval of a Certificate of Suitability (CEP) for Oxybuprocaine Hydrochloride by the European Directorate for the Quality of Medicines and Health Care (EDQM). Oxybuprocaine Hydrochloride is now commercially available to customers in Europe and other global markets with mutual recognition of the CEP.

C2P receives the approval of a Certificate of Suitability (CEP) for Tropicamide by the European Directorate for the Quality of Medicines and Health Care (EDQM).

C2 PHARMA, a global provider of ophthalmic and niche active pharmaceutical ingredients (APIs), has launched its latest API, Naphazoline Hydrochloride. The validation campaign for Naphazoline HCL was completed in June 2024. A Certificate of Suitability (CEP) is under approval while the US-Drug Master File (US-DMF) is planned for submission by November 2024 and the API dossier for Brazil (DIFA) in December 2024.

C2P is excited to announce the upcoming launch of their new API, Oxybuprocaine HCL, an API that will be manufactured by our manufacturing partner Laurus Labs.

C2 PHARMA the global leader in manufacturing and supplying ophthalmic and niche active pharmaceutical ingredients (APIs), proudly announces the approval of a Certificate of Suitability (CEP) for Tropicamide by the European Directorate for the Quality of Medicines and Health Care (EDQM). This is the first Tropicamide CEP for a European-based company, allowing C2 PHARMA to make the API commercially accessible to customers globally.

C2 PHARMA has added a new ophthalmic API to their portfolio, Naphazoline Hydrochloride. GMP samples are ready for customers worldwide.

C2 Pharma is excited to announce the upcoming launch of their new Ophthalmic API, Oxybuprocaine Hydrochloride. To learn more check out the full press release.

Your API Manufacturing Partner and Affiliate companie.

Get to know a bit about why you should work with us and what we have to offer.

C2 PHARMA has expanded their API portfolio global access with new regulatory submissions and approvals, a pending new product launch and have signed on a new CMO, SMS Lifesciences. 

Press release about C2 PHARMA's affiliate company Logistics4PHARMAs move and expansion of their GDP Bonded Warehouse to Kelsterbach, Germany.

As the global leader in Ophthalmic APIs, C2 PHARMA was asked to participate in Pharmasource’s buyer guide focused on Ophthalmics. We go to show our expertise and share a bit about our company and product portfolio. 

C2 Pharma receives the European Directorate for the Quality of Medicines and Healthcare second Certificate of Suitability for Cyclopentolate Hydrochloride, a significant achievement for our dedicated team. 

 A quick portfolio review of what we have to offer as your global leader in Ophthalmic APIs.

PharmaSource's Supplier Spotlight podcast series featuring Senior Manager of Business Development Serge Tarabay talk about C2 PHARMA's rise to becoming the Global Leader in Ophthalmic APis. 

Press release covering our approval by the CDE of a C-DMF for Digoxin, becoming China’s only European supplier of this API. The approval covers both digoxin and digoxin micronized, and it supports different dosage forms, i.e., oral and injectable drug product formulations.

This article highlights the power of internal change for a greener future. From packaging to transportation, every logistics company has the opportunity to make a difference, and Logistics4Pharma's Head of Supply Chain & Finance and Head of Operations and Customer Service give their expertise and opinions on how to become greener for the future of pharmaceutical logistics.

A featured interview with CEO of C2 PHARMA, Andrew Badrot, where he discusses his journey to starting the company and its affiliates, along with the importance of quality and quality relationships.

A press release covering the launch of affiliate ASM Research Chemicals new service development, "Devpacks". The service was developed and optimized across ten core partners to establish a standardized and robust dataset of development process steps. Now fully optimized and streamlined, the DevPack service is commercially available to help overcome resource bottlenecks and streamline API research, development, troubleshooting, and scale-up activities.